The NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study is a multicenter, randomized, controlled, clinical trial evaluating Edge Therapeutics' novel formulation, EG-1962, compared to the current standard of care, oral nimodipine, to treat patients that have suffered an aneurysmal subarachnoid hemorrhage (aSAH) from a ruptured brain aneurysm. Results of the prior phase I/2 trial have been recently released; Newton 2 is the next step in this clinical development program. The Johns Hopkins Brain Injury Outcomes team will be supporting this trial by providing online and didactic training to the outcome assessors at the clinical sites.
Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, their lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm.